- Home
- MANE vs KNSA Comparison
MANE vs KNSA Comparison
Compare MANE & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MANE | KNSA |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.9B |
| IPO Year | 2026 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MANE | KNSA |
|---|---|---|
| Price | $126.63 | $78.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $163.50 | $98.00 |
| AVG Volume (30 Days) | ★ 641.6K | 409.5K |
| Earning Date | 11-06-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | N/A | $46.66 |
| Revenue Next Year | N/A | $22.90 |
| P/E Ratio | ★ N/A | $287.23 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $36.26 | $35.53 |
| 52 Week High | $131.24 | $82.94 |
Technical Indicators
Market Signals| Indicator | MANE | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 63.22 | 56.13 |
| Support Level | $92.62 | $74.47 |
| Resistance Level | $130.52 | $81.42 |
| Average True Range (ATR) | 7.99 | 2.69 |
| MACD | 0.49 | 0.10 |
| Stochastic Oscillator | 64.33 | 79.13 |
Price Performance
Historical ComparisonAbout MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.